Real-World Evidence for a Smartwatch-based Parkinson’s Motor Assessment App in Patients Undergoing Therapy Changes
Objective: We sought to investigate patient and clinician usability of a smartwatch-based wearable motor assessment system for measuring Parkinson’s disease (PD) motor symptoms in patients undergoing…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease
Objective: To investigate the relationship of levodopa-induced dyskinesia with ADORA2A gene polymorphisms in PD patients. Background: With the progression of the disease, motor complications and…Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)
Objective: Analysis of dyskinesia as reported by PD diary, adverse events, UPDRS part IV dyskinesia score and examiner rated observation, during a phase 3 study…Comparing motor and neuropathological features of Parkinson’s disease dementia and dementia with Lewy bodies
Objective: To compare motor and neuropathological features of Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) and to determine clinical and neuropathological differences…Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis
Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…Genetic polymorphism (rs6971) in translocator protein (TSPO) and its clinical relevance in Parkinson’s disease
Objective: The objective of this study will be to identify specific clinical patterns in Parkinson’s disease patients with respect to TSPO genetic polymorphism (rs69711). Background:…Factors associated with dyskinesia in Parkinson’s disease in Mainland China
Objective: To identify the association between dyskinesia and related risk factors, the medication dosage range considered safe and treatment-related variables.To identify the association between dyskinesia…Dorsolateral striatal neuronal activity in a rat model of Parkinson`s disease with levodopa-induced dyskinesias
Objective: This study aimed to investigate the firing properties of fast spiking interneurons (FSIs) and medium spiny neurons (MSNs) of the dorsomedial striatum (DLStr) and…Efficacy of opicapone in Parkinson’s disease patients according to baseline presence of dyskinesia: a post-hoc analysis from combined BIPARK-I and II
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with or without baseline presence of dyskinesia (BPDys). Background: OPC, a…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 44
- Next Page »